195 related articles for article (PubMed ID: 26469891)
1. Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy.
Zhang GM; Zhu Y; Ma XC; Qin XJ; Wan FN; Dai B; Sun LJ; Ye DW
Medicine (Baltimore); 2015 Oct; 94(41):e1473. PubMed ID: 26469891
[TBL] [Abstract][Full Text] [Related]
2. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.
Lee H; Jeong SJ; Hong SK; Byun SS; Lee SE; Oh JJ
World J Urol; 2016 Jun; 34(6):821-7. PubMed ID: 26449784
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.
Jang WS; Cho KS; Kim KH; Yoon CY; Kang YJ; Lee JY; Ham WS; Rha KH; Hong SJ; Choi YD
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):298-304. PubMed ID: 27349499
[TBL] [Abstract][Full Text] [Related]
5. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
Manoharan M; Bird VG; Kim SS; Civantos F; Soloway MS
BJU Int; 2003 Oct; 92(6):539-44. PubMed ID: 14511029
[TBL] [Abstract][Full Text] [Related]
6. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
7. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
8. The preoperative neutrophil-to-lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy.
Cao Z; Ji J; Zhang C; Wang F; Xu H; Yu Y; Sun Y
Cancer Med; 2019 Mar; 8(3):1004-1012. PubMed ID: 30693666
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
10. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
Tully KH; Schulmeyer M; Hanske J; Reike MJ; Brock M; Moritz R; Jütte H; Tannapfel A; von Bodman C; Noldus J; Palisaar RJ; Roghmann F
BJU Int; 2021 Nov; 128(5):598-606. PubMed ID: 33961328
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
15. Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ
Eur Radiol; 2016 Aug; 26(8):2502-9. PubMed ID: 26560721
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer.
Jang WS; Cho KS; Kim MS; Yoon CY; Kang DH; Kang YJ; Jeong WS; Ham WS; Choi YD
Oncotarget; 2017 Feb; 8(7):11778-11787. PubMed ID: 28052031
[TBL] [Abstract][Full Text] [Related]
17. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
